Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 20/20 | 1.00 |
| ▸ | GABRB3 | P28472 | 20/20 | 1.00 |
| ▸ | GABRA5 | P31644 | 20/20 | 1.00 |
| ▸ | GABRA1 | P14867 | 4/20 | 1.00 |
| ▸ | GABRA3 | P34903 | 4/20 | 1.00 |
| ▸ | GABRA2 | P47869 | 4/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2430701 | 0.89 | GABRG2 (1.00) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL1377029 | 0.89 | GABRG2 (1.00) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL15203184 | 0.88 | GABRG2 (0.78) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL1378929 | 0.88 | GABRG2 (1.00) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL1375422 | 0.88 | GABRG2 (0.78) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL2826771 | 0.88 | GABRG2 (1.00) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL1377824 | 0.87 | GABRG2 (0.77) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL3872240 | 0.85 | GABRG2 (0.77) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL3871364 | 0.85 | GABRG2 (0.77) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL2431184 | 0.84 | GABRG2 (0.84) | GABRG2GABRB3GABRA5GABRA1GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183225-A1 | USE OF SELECTIVE GABA A ALPHA 5 NEGATIVE ALLOSTERIC MODULATORS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM CONDITIONS | HOFFMANN LA ROCHE (US) | 2023-06-15 | — | — | US | claimed |
| US-20210053959-A1 | USE OF SELECTIVE GABA A ALPHA 5 NEGATIVE ALLOSTERIC MODULATORS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM CONDITIONS | HOFFMANN LA ROCHE (US) | 2021-02-25 | — | — | US | claimed |
| US-20190270734-A1 | USE OF SELECTIVE GABA A ALPHA 5 NEGATIVE ALLOSTERIC MODULATORS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM CONDITIONS | F. HOFFMANN-LA ROCHE AG (CH) | 2019-09-05 | — | — | US | claimed |
| EP-2635277-A1 | USE OF ACTIVE PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM CONDITIONS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-09-11 | — | — | EP | claimed |
| EP-2457569-A1 | Use of active pharmaceutical compounds for the treatment of central nervous system conditions | F. Hoffmann-La Roche AG (CH) | 2012-05-30 | — | — | EP | claimed |
| WO-2012059482-A1 | USE OF ACTIVE PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM CONDITIONS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-05-10 | — | — | WO | claimed |
| US-20120115839-A1 | USE OF SELECTIVE GABA A ALPHA 5 NEGATIVE ALLOSTERIC MODULATORS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM CONDITIONS | HOFFMANN-LA ROCHE INC. | 2012-05-10 | — | — | US | claimed |
| JP-4751398-B2 | — | — | 2011-08-17 | — | — | JP | claimed |
| US-7507728-B2 | Halogen substituted imidazol[1,5-A][1,2,4]triazolo[1,5-D][1,4]benzodiazepine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-03-24 | — | — | US | claimed |
| EP-1807432-A1 | HALOGEN SUBSTITUTED BENZODIAZEPINE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2007-07-18 | — | — | EP | claimed |
| WO-2006045429-A1 | HALOGEN SUBSTITUTED BENZODIAZEPINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-04 | — | — | WO | claimed |
| US-20060084801-A1 | Halogen substituted imidazol[1,5-A][1,2,4]triazolo[1,5-D][1,4]benzodiazepine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-20 | — | — | US | claimed |
| EP-4126858-B1 | DIHYDRO-2-PYRROLO[3,4-C]PYRIDINE DERIVATIVES AS GABAA A5 RECEPTOR MODULATORS | RICHTER GEDEON NYRT (HU) | 2026-03-18 | — | — | EP | disclosed |
| US-20260033761-A1 | CHARACTERISATION OF NEUROLOGICAL DYSFUNCTION | HOFFMANN LA ROCHE (US) | 2026-02-05 | — | — | US | disclosed |
| EP-3856342-B1 | BICYCLIC DERIVATIVES AS GABAA A5 RECEPTOR MODULATORS | RICHTER GEDEON NYRT (HU) | 2025-12-10 | — | — | EP | disclosed |
| CN-112805063-B | Bicyclic derivatives as modulators of the GABAA A5 receptor | 吉瑞工厂 | 2024-02-23 | — | — | CN | disclosed |
| US-7507728-B2 | Halogen substituted imidazol[1,5-A][1,2,4]triazolo[1,5-D][1,4]benzodiazepine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-03-24 | — | — | US | disclosed |
| EP-1807432-A1 | HALOGEN SUBSTITUTED BENZODIAZEPINE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2007-07-18 | — | — | EP | disclosed |
| WO-2006045429-A1 | HALOGEN SUBSTITUTED BENZODIAZEPINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-04 | — | — | WO | disclosed |
| US-20060084801-A1 | Halogen substituted imidazol[1,5-A][1,2,4]triazolo[1,5-D][1,4]benzodiazepine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115839-A1 | USE OF SELECTIVE GABA A ALPHA 5 NEGATIVE ALLOSTERIC MODULATORS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM CONDITIONS | GABRA5, GABRB1, GABRE | GABRG2 18/4885GABRB3 6/4885GABRA5 1/4885 |
| US-20210053959-A1 | USE OF SELECTIVE GABA A ALPHA 5 NEGATIVE ALLOSTERIC MODULATORS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM CONDITIONS | GABRA5, GABRB1, GABRE | GABRG2 18/4885GABRB3 6/4885GABRA5 1/4885 |
| US-20260033761-A1 | CHARACTERISATION OF NEUROLOGICAL DYSFUNCTION | PMP22, PARK7, NCS1 | GABRG2 425/4885GABRB3 331/4885GABRA5 101/4885 |
| US-20060084801-A1 | Halogen substituted imidazol[1,5-A][1,2,4]triazolo[1,5-D][1,4]benzodiazepine derivatives | GABRA1, GABRA4, GABRA5 | GABRG2 24/4885GABRB3 10/4885GABRA5 3/4885 |
| US-20230183225-A1 | USE OF SELECTIVE GABA A ALPHA 5 NEGATIVE ALLOSTERIC MODULATORS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM CONDITIONS | GABRA5, GABRB1, GABRE | GABRG2 18/4885GABRB3 6/4885GABRA5 1/4885 |
| US-20190270734-A1 | USE OF SELECTIVE GABA A ALPHA 5 NEGATIVE ALLOSTERIC MODULATORS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM CONDITIONS | GABRA5, GABRB1, GABRE | GABRG2 18/4885GABRB3 6/4885GABRA5 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.